KRAS and non-small cell lung carcinoma: Here, we used genetic mouse models of KRAS-driven NSCLC and PDAC to underpin the efficacy of BET inhibitors against KRAS-driven malignancies and preclinically validate their use in tumors presenting mutations in KRAS.